251. Urea cycle disorder Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 54 / Drugs : 61 - (DrugBank : 15) / Drug target genes : 3 - Drug target pathways : 28
Urea cycle disorder and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
| ID | Diseases (Sorted by drug repositionability) |
|---|---|
| 251 | Urea cycle disorder |
| 300 | IgG4-related disease |
| 35 | Pemphigus |
| 271 | Ankylosing spondylitis |
| 78 | Hypopituitarism |
| 11 | Myasthenia gravis |
| 107 | Juvenile idiopathic arthritis |
| 298 | Hereditary pancreatitis |
| 3 | Spinal muscular atrophy |
| 113 | Muscular dystrophy |
| 222 | Primary nephrotic syndrome |
| 226 | Interstitial cystitis with Hunners ulcer |
| 70 | Spinal stenosis |
| 65 | Primary immunodeficiency |
| 299 | Cystic fibrosis |
| 86 | Pulmonary arterial hypertension |
| 51 | Scleroderma |
| 49 | Systemic lupus erythematosus |
| 97 | Ulcerative colitis |
| 96 | Crohn disease |
| 46 | Malignant rheumatoid arthritis |
| 6 | Parkinson disease |
| 13 | Multiple sclerosis/Neuromyelitis optica |
| 337 | Homocystinuria |
| 22 | Moyamoya disease |
| 225 | Congenital nephrogenic diabetes insipidus |
| 256 | Muscle glycogenosis |
| 210 | Single Ventricle |
| 231 | Alpha-1-antitrypsin deficiency |
| 158 | Tuberous sclerosis |
| 296 | Biliary atresia |
| 21 | Mitochondrial disease |
| 58 | Hypertrophic cardiomyopathy |
| 206 | Fragile X syndrome |
| 5 | Progressive supranuclear palsy |
| 28 | Systemic amyloidosis |
| 34 | Neurofibromatosis |
| 2 | Amyotrophic lateral sclerosis |
| 220 | Rapidly progressive glomerulonephritis |
| 30 | Distal myopathy |
| 245 | Propionic acidemia |